ΠŸΡ€Π΅Ρ’ΠΈ Π½Π° ΡΠ°Π΄Ρ€ΠΆΠ°Ρ˜

Sertindol

Π‘ Π’ΠΈΠΊΠΈΠΏΠ΅Π΄ΠΈΡ˜Π΅, слободнС Π΅Π½Ρ†ΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΡ˜Π΅
Sertindol
Klinički podaci
Prodajno imeSerdolect, Serlect
Drugs.comMonografija
Identifikatori
CAS broj106516-24-9 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°
ATC kodN05AE03 (WHO)
PubChemCID 60149
IUPHAR/BPS98
DrugBankDB06144 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°
ChemSpider54229 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°
KEGGC07567 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°
ChEBICHEBI:9122 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°
ChEMBLCHEMBL12713 Π—Π΅Π»Π΅Π½Π° ΠΊΠ²Π°Ρ‡ΠΈΡ†Π°Π”Π°

Sertindol je organsko jedinjenje, koje sadrΕΎi 24 atoma ugljenika i ima molekulsku masu od 440,941 Da.[1][2][3][4][5][6][7][8][9]

Osobine

[ΡƒΡ€Π΅Π΄ΠΈ | ΡƒΡ€Π΅Π΄ΠΈ ΠΈΠ·Π²ΠΎΡ€]
Osobina Vrednost
Broj akceptora vodonika 2
Broj donora vodonika 1
Broj rotacionih veza 5
Particioni koeficijent[10] (ALogP) 4,7
Rastvorljivost[11] (logS, log(mol/L)) -6,4
Polarna povrΕ‘ina[12] (PSA, Γ…2) 40,5

Reference

[ΡƒΡ€Π΅Π΄ΠΈ | ΡƒΡ€Π΅Π΄ΠΈ ΠΈΠ·Π²ΠΎΡ€]
  1. ^ Kane JM, Tamminga CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs. Kane, J. M.; Tamminga, C. A. (Π½ΠΎΠ²Π΅ΠΌΠ±Π°Ρ€ 1997). β€žSertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic”. Expert Opinion on Investigational Drugs. 6 (11): 1729β€”41. PMID 15989577. doi:10.1517/13543784.6.11.1729. 
  2. ^ Lewis R, Bagnall AM, Leitner M: Sertindole for schizophrenia. Cochrane Database Syst Rev. 20;(3):CD001715. Lewis, R.; Bagnall, A. M.; Leitner, M. (2005 Jul). β€žSertindole for schizophrenia”. The Cochrane Database of Systematic Reviews (3): CD001715. PMC 7025766 Π‘Π»ΠΎΠ±ΠΎΠ΄Π°Π½ приступ. PMID 16034864. doi:10.1002/14651858.CD001715.pub2.  ΠŸΡ€ΠΎΠ²Π΅Ρ€ΠΈΡ‚Π΅ врСдност ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚(Π°)Ρ€Π° Π·Π° Π΄Π°Ρ‚ΡƒΠΌ: |date= (ΠΏΠΎΠΌΠΎΡ›)
  3. ^ Perquin LN: Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. Perquin, L. N. (Π½ΠΎΠ²Π΅ΠΌΠ±Π°Ρ€ 2005). β€žTreatment with the new antipsychotic sertindole for late-occurring undesirable movement effects”. International Clinical Psychopharmacology. 20 (6): 335β€”8. PMID 16192844. doi:10.1097/00004850-200511000-00010. 
  4. ^ Murdoch D, Keating GM: Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;Murdoch, D.; Keating, G. M. (2006). β€žSertindole : A review of its use in schizophrenia”. CNS Drugs. 20 (3): 233β€”55. PMID 16529528. doi:10.2165/00023210-200620030-00005. 
  5. ^ Sertindole: new drug. Another atypical neuroleptic; QT prolongation. Prescrire Int. β€žSertindole: New drug. Another "atypical" neuroleptic; QT prolongation”. Prescrire International. 16 (88): 59β€”62. Π°ΠΏΡ€ΠΈΠ» 2007. PMID 17458045. 
  6. ^ Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. LindstrΓΆm, E.; Levander, S. (сСптСмбар 2006). β€žSertindole: Efficacy and safety in schizophrenia”. Expert Opinion on Pharmacotherapy. 7 (13): 1825β€”34. PMID 16925508. doi:10.1517/14656566.7.13.1825. 
  7. ^ Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. Hertel, P. (Π΄Π΅Ρ†Π΅ΠΌΠ±Π°Ρ€ 2006). β€žComparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: Mechanism of action”. Synapse (New York, N.Y.). 60 (7): 543β€”52. PMID 16952163. doi:10.1002/syn.20322. 
  8. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). β€žDrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035β€”41. PMC 3013709 Π‘Π»ΠΎΠ±ΠΎΠ΄Π°Π½ приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  9. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). β€žDrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901β€”6. PMC 2238889 Π‘Π»ΠΎΠ±ΠΎΠ΄Π°Π½ приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  10. ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). β€žPrediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762β€”3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 
  11. ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). β€žEstimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488β€”1493. PMID 11749573. doi:10.1021/ci000392t. 
  12. ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). β€žFast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714β€”3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

[ΡƒΡ€Π΅Π΄ΠΈ | ΡƒΡ€Π΅Π΄ΠΈ ΠΈΠ·Π²ΠΎΡ€]

SpoljaΕ‘nje veze

[ΡƒΡ€Π΅Π΄ΠΈ | ΡƒΡ€Π΅Π΄ΠΈ ΠΈΠ·Π²ΠΎΡ€]
Molimo Vas, obratite paΕΎnju na vaΕΎno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).
ΠŸΡ€Π΅ΡƒΠ·Π΅Ρ‚ΠΎ са β€žhttps://sr.wikipedia.org/w/index.php?title=Sertindol&oldid=31690179”